# EDGAR Filing Document

**Accession Number:** 0000093314
**File Stem:** 0001477932-23-001175
**Filing Date:** 2023-2
**Character Count:** 124748
**Document Hash:** 94ee85ad133b7e4fb087f6d7541b83ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001175.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001477932-23-001175

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VOLITIONRX LTD
- **CENTRAL INDEX KEY:** 0000093314
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 911949078
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-259783
- **FILM NUMBER:** 23648003

**BUSINESS ADDRESS:**
- **STREET 1:** 1489 WEST WARM SPRINGS ROAD
- **STREET 2:** SUITE 110
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89014
- **BUSINESS PHONE:** 1 (646) 650-1351

**MAIL ADDRESS:**
- **STREET 1:** 1489 WEST WARM SPRINGS ROAD
- **STREET 2:** SUITE 110
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STANDARD CAPITAL CORP
- **DATE OF NAME CHANGE:** 19990812

**Filed Pursuant to Rule 424(b)(5)**

**Registration No. 333-259783**

**PROSPECTUS SUPPLEMENT** 

**(To Prospectus dated November 8, 2021)** 

**4,300,000 Shares**

![](vnrx_424b5img4.jpg)

**VOLITIONRX LIMITED**

**Common Stock**

__________________________________

We are offering 4,300,000 shares of our common stock, par value $0.001 per share, at a price of $1.75 per share.

Our common stock is listed on the NYSE American Market under the symbol "VNRX." On February 16, 2023, the last reported sale price of our common stock on the NYSE American Market was $2.04 per share.

---

| | | |
|:---|:---|:---|
|  | **Per Share** | **Total** |
| Public offering price | $1.75 | $7525000 |
| &nbsp;&nbsp;&nbsp; Underwriting discounts and commissions<sup>(1)</sup> | $0.1225 | $526750 |
| &nbsp;&nbsp;&nbsp; Proceeds, before expenses, to us | $1.6275 | $6998250 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>(1)</sup> We have agreed to reimburse the underwriter for certain expenses. See "*Underwriting*" on page S-11 of this prospectus supplement for additional disclosures regarding underwriting discounts, commissions and estimated offering expenses. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>(1)</sup> We have agreed to reimburse the underwriter for certain expenses. See "*Underwriting*" on page S-11 of this prospectus supplement for additional disclosures regarding underwriting discounts, commissions and estimated offering expenses. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>(1)</sup> We have agreed to reimburse the underwriter for certain expenses. See "*Underwriting*" on page S-11 of this prospectus supplement for additional disclosures regarding underwriting discounts, commissions and estimated offering expenses. |

---

Certain family members of one of our directors have agreed to purchase an aggregate of 234,000 shares in this offering at the same price per share offered to the public.

We have granted the underwriter an option for a period of 30 days from the date of this prospectus supplement to purchase up to an additional 645,000 shares of common stock to cover overallotments at the public offering price, less underwriting discounts and commissions. If the underwriter exercises its option in full, the total underwriting discounts and commissions payable by us will be approximately $605,763, and the total proceeds to us, before expenses, will be approximately $8,047,988.

**Investing in our common stock involves a high degree of risk. You should carefully consider all of the information set forth in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference in this prospectus supplement before deciding to invest in our common stock. Please see "*Risk Factors*" on page S-5 of this prospectus supplement and page 3 of the accompanying base prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying base prospectus to read about factors you should consider before buying shares of our common stock.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities being offered by this prospectus supplement or the prospectus to which it relates, or determined if this prospectus supplement or the prospectus to which it relates are truthful or complete. Any representation to the contrary is a criminal offense.** 

The underwriter expects to deliver the shares of common stock against payment on or about February 22, 2023, subject to customary closing conditions.

**Newbridge Securities Corporation**

**The date of this prospectus supplement is February 17, 2023.** 

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| **PROSPECTUS SUPPLEMENT**  |  |
| [ABOUT THIS PROSPECTUS SUPPLEMENT](#about1) | S-1 |
| [PROSPECTUS SUPPLEMENT SUMMARY](#pro1) | S-3 |
| [RISK FACTORS](#risk1) | S-5 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION](#caot1) | S-6 |
| [USE OF PROCEEDS](#use1) | S-7 |
| [DIVIDEND POLICY](#div1) | S-8 |
| [DILUTION](#dil1) | S-9 |
| [DESCRIPTION OF COMMON STOCK](#desc1) | S-10 |
| [UNDERWRITING](#under1) | S-11 |
| [LEGAL MATTERS](#leg1) | S-14 |
| [EXPERTS](#exp1) | S-14 |
| [INCORPORATION OF CERTAIN INFORMATION BY REFERENCE](#incorp1) | S-14 |
| [WHERE YOU CAN FIND MORE INFORMATION](#where1) | S-15 |
| **PROSPECTUS**  |  |
| [ABOUT THIS PROSPECTUS](#about2) | 1 |
| [PROSPECTUS SUMMARY](#pro2) | 2 |
| [RISK FACTORS](#risk2) | 3 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION](#cout2) | 4 |
| [USE OF PROCEEDS](#use2) | 5 |
| [GENERAL DESCRIPTION OF SECURITIES](#gen2) | 6 |
| [DESCRIPTION OF CAPITAL STOCK](#disc2) | 7 |
| [DESCRIPTION OF WARRANTS](#disc3) | 9 |
| [DESCRIPTION OF UNITS](#disc4) | 10 |
| [PLAN OF DISTRIBUTION](#plan2) | 11 |
| [LEGAL MATTERS](#leg2) | 13 |
| [EXPERTS](#exp2) | 13 |
| [INCORPORATION OF CERTAIN INFORMATION BY REFERENCE](#incorp2) | 14 |
| [WHERE YOU CAN FIND MORE INFORMATION](#ehere2) | 15 |

---

**ABOUT THIS PROSPECTUS SUPPLEMENT**

This document is part of a registration statement that was filed with the Securities and Exchange Commission, or the SEC, using a "shelf" registration process and consists of two parts. The first part is the prospectus supplement, including the documents incorporated by reference herein, which describes the specific terms of this offering. The second part, the accompanying prospectus, including the documents incorporated by reference therein, provides more general information. In general, when we refer only to the prospectus, we are referring to both parts of this document combined.

Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated by reference herein and therein, as well as the additional information described under the heading "*Where You Can Find More Information*." These documents contain information you should carefully consider when deciding whether to invest in our common stock.

This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent there is a conflict between the information contained in this prospectus supplement and the accompanying prospectus, you should rely on information contained in this prospectus supplement, provided that if any statement in, or incorporated by reference into, one of these documents is inconsistent with a statement in another document having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.

**You should rely only on the information contained in this prospectus supplement, the accompanying prospectus, any document incorporated by reference herein or therein, or any free writing prospectuses we may provide to you in connection with this offering. Neither we nor the underwriter has authorized anyone to provide you with any different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus supplement and the accompanying prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus supplement, the accompanying prospectus, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and prospects may have changed since those respective dates.**

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

This prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the shares of common stock to which it relates, nor do this prospectus supplement and the accompanying prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

Unless otherwise indicated, information contained in or incorporated by reference into this prospectus concerning our industry and the markets in which we operate, including market position and market opportunity, is based on information from our management's estimates, as well as from industry publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, while we believe that information contained in industry publications, surveys and studies has been obtained from reliable sources, the accuracy and completeness of such information is not guaranteed, and we have not independently verified any of the data contained in these third-party sources.

---

| |
|:---|
| S-1 |
| *[**Table of Contents**](#toc1)* |

---

This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, include statements that are based on various assumptions and estimates that are subject to numerous known and unknown risks and uncertainties. Some of these risks and uncertainties are described in the section entitled "*Risk Factors*" beginning on page S-5 of this prospectus supplement and in the section entitled "Risk Factors" starting on page 13 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, or our Annual Report, as well as the other documents we file with the SEC. These and other important factors could cause our future results to be materially different from the results expected as a result of, or implied by, these assumptions and estimates. You should read the information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus, and the documents incorporated by reference herein and therein, completely and with the understanding that future results may be materially different from and worse than what we expect. See the information included under the heading "*Cautionary Note Regarding Forward-Looking Information*."

This prospectus does not contain all of the information included in the registration statement of which this prospectus is a part. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. The registration statement containing this prospectus supplement, including the exhibits to the registration statement, provides additional information about us and the securities offered pursuant to this prospectus supplement. The registration statement, including the exhibits, can be read on the SEC's website mentioned under the heading "*Where You Can Find More Information*."

Unless we state otherwise or the context indicates otherwise, references to the "Company," "VolitionRx," "Volition," "we," "us," and "our" in this prospectus refer to VolitionRx Limited and its wholly owned subsidiaries, Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Global Services SRL, Volition Diagnostics UK Limited, Volition America, Inc., and Volition Germany GmbH, and its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC. Our fiscal year ends on December 31 of each calendar year. Nucleosomics<sup>TM</sup> and Nu.Q<sup>®</sup> and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to in this prospectus are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

---

| |
|:---|
| S-2 |
| *[**Table of Contents**](#toc1)* |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **PROSPECTUS SUPPLEMENT SUMMARY**<br>*This prospectus supplement summary discusses the key aspects of the offering and highlights certain information appearing elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we incorporate by reference herein and therein. However, as this is a summary, it does not contain all of the information that you should consider before deciding to invest in our common stock. You are encouraged to carefully read this entire prospectus, the accompanying prospectus, any free writing prospectus that we have been authorized to use and the documents incorporated by reference herein and in the accompanying prospectus. You should pay special attention to the information provided under the headings (i) "Risk Factors" in this prospectus supplement and in the accompanying prospectus and in our Annual Report as well as in the other documents we file with the SEC, and (ii) "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as our financial statements and the related notes thereto and the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.*<br>**Overview** <br>We are a multi-national epigenetics company that applies our Nucleosomics™ platform through our subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. <br>Our blood tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids, since changes in these parameters are an indication that disease is present. While we are primarily focused on human diagnostics and monitoring, we also have a subsidiary focused on animal diagnostics and monitoring. <br>We have five key pillars of focus, all of which use the same proprietary Nu.Q<sup>®</sup> platform to commercialize in different areas. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **PROSPECTUS SUPPLEMENT SUMMARY**<br>*This prospectus supplement summary discusses the key aspects of the offering and highlights certain information appearing elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we incorporate by reference herein and therein. However, as this is a summary, it does not contain all of the information that you should consider before deciding to invest in our common stock. You are encouraged to carefully read this entire prospectus, the accompanying prospectus, any free writing prospectus that we have been authorized to use and the documents incorporated by reference herein and in the accompanying prospectus. You should pay special attention to the information provided under the headings (i) "Risk Factors" in this prospectus supplement and in the accompanying prospectus and in our Annual Report as well as in the other documents we file with the SEC, and (ii) "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as our financial statements and the related notes thereto and the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus.*<br>**Overview** <br>We are a multi-national epigenetics company that applies our Nucleosomics™ platform through our subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. Our mission is to save lives and improve outcomes for millions of people and animals worldwide. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. <br>Our blood tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids, since changes in these parameters are an indication that disease is present. While we are primarily focused on human diagnostics and monitoring, we also have a subsidiary focused on animal diagnostics and monitoring. <br>We have five key pillars of focus, all of which use the same proprietary Nu.Q<sup>®</sup> platform to commercialize in different areas. |
| ·  | **Nu.Q<sup>®</sup> Vet** – cost-effective, easy-to-use cancer screening blood test for dogs and other animals |
| ·  | **Nu.Q<sup>®</sup> NETs** – monitoring the immune system to save lives |
| ·  | **Nu.Q<sup>®</sup>** – detecting cancer early to save lives |
| ·  | **Nu.Q<sup>®</sup> Capture** – capturing and concentrating samples for more accurate diagnosis |
| ·  | **Nu.Q<sup>®</sup> Discover** – a completed solution to profiling nucleosomes |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> Our research and development activities are centered in Belgium, with an innovation laboratory in California, and additional offices in Nevada, London, and Singapore, where we focus on bringing our diagnostic and disease monitoring products to market.<br>**Recent Developments**<br>***Certain Preliminary Financial Results as of December 31, 2022***<br>Although we have not finalized our full financial results for the three months and fiscal year ended December 31, 2022, we expect to report that we had approximately $10.9 million in cash and cash equivalents as of December 31, 2022.<br>The information above is based on preliminary unaudited information and estimates for the three months and fiscal year ended December 31, 2022, is not a comprehensive statement of our financial results for this period, and is subject to change pending completion of our financial closing procedures, final adjustments, completion of the review of our financial statements and other developments that may arise between now and the time the review of our financial statements is completed. This preliminary estimate may change and the change may be material. Our expectation with respect to our cash and cash equivalents at December 31, 2022 is based upon management estimates and is the responsibility of management. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates. Our actual results for the three months and fiscal year ended December 31, 2022, will not be available until after this offering is completed.<br>***Commercial Agreements***<br>In October 2022, we entered into a supply agreement with IDEXX Laboratories Inc., or IDEXX, to make Nu.Q<sup>®</sup> Vet Cancer Tests available to customers through IDEXX's global reference laboratory network. IDEXX launched the product to customers in the United States in January 2023 and we anticipate IDEXX rolling out the product to customers in other countries later in 2023. We have also partnered with DNATech, Portugal, and, through our license agreement with Heska Corporation ("Heska"), with SCIL Lab Europe, to launch the Nu.Q<sup>®</sup> Vet Cancer Test to customers in Europe in November 2022.<br>On February 16, 2023, we announced that our Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska pursuant to that certain License and Supply Agreement that Belgian Volition SRL entered into with Heska on March 28, 2022, under which we, among other things, granted Heska worldwide exclusive rights to sell the test at the point-of-care to screen for cancer in dogs. This pre-order launch is a further step towards potential additional milestone payments to the Company under the agreement with Heska. <br>***At-the-Market Offering***<br>On May 20, 2022, we entered into an equity distribution agreement, or the 2022 EDA, with Jefferies LLC, or Jefferies, under which we may, from time to time, offer and sell common stock having an aggregate offering value of up to $25.0 million, through an "at-the-market" offering with Jefferies pursuant our shelf registration statement on Form S-3, as amended (declared effective by the SEC on November 8, 2021, File No. 333-259783). To date, 630,532 shares of our common stock have been sold under the 2022 EDA and no additional shares may be offered or sold for a period of 60 days after the date of this prospectus supplement.  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> Our research and development activities are centered in Belgium, with an innovation laboratory in California, and additional offices in Nevada, London, and Singapore, where we focus on bringing our diagnostic and disease monitoring products to market.<br>**Recent Developments**<br>***Certain Preliminary Financial Results as of December 31, 2022***<br>Although we have not finalized our full financial results for the three months and fiscal year ended December 31, 2022, we expect to report that we had approximately $10.9 million in cash and cash equivalents as of December 31, 2022.<br>The information above is based on preliminary unaudited information and estimates for the three months and fiscal year ended December 31, 2022, is not a comprehensive statement of our financial results for this period, and is subject to change pending completion of our financial closing procedures, final adjustments, completion of the review of our financial statements and other developments that may arise between now and the time the review of our financial statements is completed. This preliminary estimate may change and the change may be material. Our expectation with respect to our cash and cash equivalents at December 31, 2022 is based upon management estimates and is the responsibility of management. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates. Our actual results for the three months and fiscal year ended December 31, 2022, will not be available until after this offering is completed.<br>***Commercial Agreements***<br>In October 2022, we entered into a supply agreement with IDEXX Laboratories Inc., or IDEXX, to make Nu.Q<sup>®</sup> Vet Cancer Tests available to customers through IDEXX's global reference laboratory network. IDEXX launched the product to customers in the United States in January 2023 and we anticipate IDEXX rolling out the product to customers in other countries later in 2023. We have also partnered with DNATech, Portugal, and, through our license agreement with Heska Corporation ("Heska"), with SCIL Lab Europe, to launch the Nu.Q<sup>®</sup> Vet Cancer Test to customers in Europe in November 2022.<br>On February 16, 2023, we announced that our Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska pursuant to that certain License and Supply Agreement that Belgian Volition SRL entered into with Heska on March 28, 2022, under which we, among other things, granted Heska worldwide exclusive rights to sell the test at the point-of-care to screen for cancer in dogs. This pre-order launch is a further step towards potential additional milestone payments to the Company under the agreement with Heska. <br>***At-the-Market Offering***<br>On May 20, 2022, we entered into an equity distribution agreement, or the 2022 EDA, with Jefferies LLC, or Jefferies, under which we may, from time to time, offer and sell common stock having an aggregate offering value of up to $25.0 million, through an "at-the-market" offering with Jefferies pursuant our shelf registration statement on Form S-3, as amended (declared effective by the SEC on November 8, 2021, File No. 333-259783). To date, 630,532 shares of our common stock have been sold under the 2022 EDA and no additional shares may be offered or sold for a period of 60 days after the date of this prospectus supplement.  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Corporate Information**<br>We are a Delaware corporation. Our executive offices are located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014, and our telephone number is +1 (646) 650-1351. We maintain a website at *www.volition.com*. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to such reports are available to you free of charge through the "Investors" section of *www.volition.com* as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities. We have included our website address only as an inactive textual reference and do not intend it to be an active link to our website | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Corporate Information**<br>We are a Delaware corporation. Our executive offices are located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014, and our telephone number is +1 (646) 650-1351. We maintain a website at *www.volition.com*. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to such reports are available to you free of charge through the "Investors" section of *www.volition.com* as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase our securities. We have included our website address only as an inactive textual reference and do not intend it to be an active link to our website |

---

---

| |
|:---|
| S-3 |
| *[**Table of Contents**](#toc1)* |

---

---

| | |
|:---|:---|
| <br> **The Offering** | <br> **The Offering** |
| Issuer: | VolitionRx Limited |
| <br> Offering price: | <br> $1.75 per share |
| Common stock offered by us: | 4,300,000 shares (or 4,945,000 shares if the underwriter exercises in full its option to purchase additional shares) |
| Common stock to be outstanding immediately after this offering: | 61,796,003 shares (or 62,441,003 shares if the underwriter exercises in full its option to purchase additional shares) |
| Option to purchase additional shares: | The underwriter has an option to purchase a maximum of 645,000 additional shares of common stock from us to cover over-allotments. The underwriter can exercise this option at any time within 30 days from the date of this prospectus supplement. |
| Use of proceeds: | We intend to use the net proceeds from this offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions. For additional information, refer to the section entitled "*Use of Proceeds*" on page S-7. |
| Risk factors: | Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the section entitled "*Risk Factors*" beginning on page S-5 of this prospectus supplement and page 13 of our Annual Report, as well as the risks and uncertainties described in the other documents we file with the SEC. |
| NYSE American Market symbol: | VNRX |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain family members of one of our directors have agreed to purchase an aggregate of 234,000 shares in this offering at the same price per share offered to the public.<br>Unless otherwise indicated, the number of shares of our common stock to be outstanding immediately after this offering is based on 57,496,003 shares of our common stock outstanding as of September 30, 2022, but excludes the following as of such date: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain family members of one of our directors have agreed to purchase an aggregate of 234,000 shares in this offering at the same price per share offered to the public.<br>Unless otherwise indicated, the number of shares of our common stock to be outstanding immediately after this offering is based on 57,496,003 shares of our common stock outstanding as of September 30, 2022, but excludes the following as of such date: |
| 5,025,003 shares of our common stock issuable upon the exercise of options under our 2011 Equity Incentive Plan and 2015 Stock Incentive Plan, outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.87 per share; | 5,025,003 shares of our common stock issuable upon the exercise of options under our 2011 Equity Incentive Plan and 2015 Stock Incentive Plan, outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.87 per share; |
| 539,000 shares of our common stock issuable upon the warrants outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.80 per share; | 539,000 shares of our common stock issuable upon the warrants outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.80 per share; |
| 738,135 restricted stock units outstanding under our 2015 Stock Incentive Plan as of September 30, 2022, with a weighted average price of $3.02 per share; and | 738,135 restricted stock units outstanding under our 2015 Stock Incentive Plan as of September 30, 2022, with a weighted average price of $3.02 per share; and |
| an aggregate of 1,928,740 shares of common stock reserved for future issuance as of September 30, 2022 under our 2015 Stock Incentive Plan. | an aggregate of 1,928,740 shares of common stock reserved for future issuance as of September 30, 2022 under our 2015 Stock Incentive Plan. |
| Unless otherwise indicated, this prospectus reflects and assumes the following: | Unless otherwise indicated, this prospectus reflects and assumes the following: |
| no additional issuances, exercises or forfeitures of options and warrants, other than as described above; | no additional issuances, exercises or forfeitures of options and warrants, other than as described above; |
| no exercise of the outstanding options and warrants described above; and | no exercise of the outstanding options and warrants described above; and |
| no exercise by the underwriter of its option to purchase additional shares of our common stock. | no exercise by the underwriter of its option to purchase additional shares of our common stock. |

---

---

| |
|:---|
| S-4 |
| *[**Table of Contents**](#toc1)* |

---

**RISK FACTORS**

*Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below, together with all of the other information included in this prospectus supplement, the accompanying prospectus, and the information incorporated by reference herein and therein, including the risks described under the heading "Risk Factors" beginning on page 13 of our Annual Report, as well as in the other documents we file with the SEC.* 

*If any of the risks described below, or those incorporated by reference into this prospectus, actually occur, our business, financial condition, results of operations and future prospects could suffer. In that case, the trading price of our common stock may decline and you may lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business, financial condition, results of operations and future prospects. Certain statements below are forward-looking statements. See the information included under the heading "Cautionary Note Regarding Forward-Looking Information."*

**Risks Related to Our Common Stock and this Offering**

***Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment. You may experience further dilution if we issue additional common stock in the future.***

The public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock before giving effect to this offering. Our pro forma net tangible book value as of September 30, 2022 was approximately $4.2 million, or $0.07 per share. After giving effect to the sale of 4,300,000 shares of our common stock at the public offering price of $1.75 per share and after deducting the underwriting fees and estimated offering expenses payable by us, if you purchase our common stock in this offering, you will incur immediate substantial dilution of approximately $1.57 per share. Furthermore, if outstanding options or warrants are exercised, you could experience further dilution. See the information included under the heading "*Dilution*."

If we issue additional shares of common stock, or securities exercisable for shares of common stock, including under our "at-the-market" offering program, our stockholders, including investors who purchase shares of common stock in this offering, may experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering.

***A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price for our common stock.***

Sales of a substantial number of shares of our common stock in the public market following this offering, or the perception that such sales might occur, could cause the market price of our common stock to decline. A substantial number of the outstanding shares of our common stock are, and the shares of common stock sold in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act.

Upon the completion of this offering, approximately 6,893,482 shares of our outstanding common stock beneficially owned by our executive officers and directors will be subject to lock-up agreements with the underwriter of this offering that restrict the sale of shares of our common stock by those parties for a period of three months after the date of this prospectus supplement. However, all of the shares sold in this offering and the remaining shares of our common stock outstanding prior to this offering (which include certain shares that are held by our affiliates other than our officers and directors) will not be subject to lock-up agreements with the underwriter and, except to the extent such shares are subject to lock-up agreements, will be freely tradable without restriction under the Securities Act. The market price of our common stock could decline as a result of sales by our stockholders in the market following completion of this offering or the perception that these sales could occur.

***Management will have broad discretion to determine how to use the funds raised in this offering, and may use them in ways that may not enhance our operating results or the price of our common stock.***

Our management will have broad discretion over the use of proceeds from this offering, and we could spend the proceeds from this offering in ways our stockholders may not agree with or that do not yield a favorable return. We intend to use the net proceeds of this offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions. However, our use of these proceeds may differ substantially from our current plans. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could have a material adverse effect on our business, financial condition, operating results and cash flow, and which could cause our stock price to decline.

***Because we do not currently intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.***

We have never paid cash dividends on our common stock. We currently intend to retain any future earnings to fund the development and growth of our business. Additionally, our ability to pay dividends is limited by restrictions on our ability to pay dividends and make certain other restricted payments under the terms of our term loan. Accordingly, while payment of dividends rests within the discretion of our board of directors, no cash dividends on our common shares have been declared or paid by us and we have no intention of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.

---

| |
|:---|
| S-5 |
| *[**Table of Contents**](#toc1)* |

---

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION**

This prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein, contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this prospectus supplement, the accompanying prospectus, or the documents incorporated by reference herein or therein, are forward-looking statements. Such statements are typically characterized by terminology such as "anticipate," "believe," "continue," "could," "estimate(s)," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "seek," "should," "strategy," "will," and similar expressions.

Forward-looking statements also include the assumptions underlying or relating to such statements. In particular, forward-looking statements contained in this prospectus supplement and the accompanying prospectus relate to, among other things, our future or assumed financial condition, results of operations, liquidity, business forecasts and plans, research and product development plans, manufacturing plans, strategic plans and objectives, capital needs and financing plans, product launches, regulatory approvals, competitive environment, and the application of accounting guidance. We caution you that the foregoing list may not include all of the forward-looking statements made in this prospectus supplement and the accompanying prospectus.

Our forward-looking statements are based on our management's current assumptions and expectations about future events and trends, which affect or may affect our business, strategy, operations or financial performance. Although we believe that these forward-looking statements are based upon reasonable assumptions, they are subject to numerous known and unknown risks and uncertainties and are made in light of information currently available to us. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section entitled "*Risk Factors*" beginning on page S-5 of this prospectus and page 13 of our Annual Report, as well as those described in the other documents we file with the SEC. You should read this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein, completely and with the understanding that our actual future results may be materially different from and worse than what we expect.

Some significant factors that may impact our estimates and forward-looking statements include:

· Our inability to generate any significant revenue or achieve profitability;

· Our need to raise additional capital in the future;

· Our expectations to expand our product development, research and sales and marketing capabilities could give rise to difficulties in managing our growth;

· Our limited experience with direct sales and marketing;

· The material weaknesses in our internal control over financial reporting that we have identified;

· The possibility that we may not be able to continue to operate, as indicated by the "going concern" opinion from our auditors;

· Our ability to successfully develop, manufacture, market, and sell our future products;

· Our ability to timely obtain necessary regulatory clearances or approvals to distribute and market our future products;

· The acceptance by the marketplace of our future products;

· The highly competitive and rapidly changing nature of the cancer diagnostics market;

· Our reliance on third parties to manufacture and supply our intended products, and such manufacturers' dependence on third party suppliers;

· Our dependence on third-party distributors;

· Protection of our patents, intellectual property and trade secrets; and

· Business disruptions and economic and other uncertainties surrounding the COVID-19 pandemic.

Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they were made, and, except to the extent required by law or the rules of the NYSE American Market, we undertake no obligation to update or review any forward-looking statement because of new information, future events or other factors. You should, however, review the risks and uncertainties we describe in the reports we will file from time to time with the SEC, after the date of this prospectus supplement. For additional information, refer to the section entitled "*Where You Can Find More Information*."

Forward-looking statements involve risks and uncertainties and are not guarantees of future performance. As a result of such risks and uncertainties, including those described above, the forward-looking statements discussed in this prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein might not occur and our future results and our performance may differ materially from those expressed in these forward-looking statements due to, but not limited to, the factors mentioned above. Because of these uncertainties, you should not place undue reliance on these forward-looking statements when making an investment decision.

---

| |
|:---|
| S-6 |
| *[**Table of Contents**](#toc1)* |

---

**USE OF PROCEEDS**

We estimate that the net proceeds from this offering will be approximately $6.8 million, or approximately $7.8 million if the underwriter fully exercises its option to purchase additional shares, after deducting the underwriting discounts and estimated offering expenses payable by us.

We currently anticipate that we will use the net proceeds received by us for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions. Our expected use of the net proceeds from this offering is based upon our present plans and business condition. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of proceeds will vary depending on numerous factors, including the factors described under the heading "*Risk Factors*" beginning on page S-5 of this prospectus supplement and page 13 of our Annual Report, as well as the other documents we file with the SEC. As a result, management will retain broad discretion over the allocation of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds.

---

| |
|:---|
| S-7 |
| *[**Table of Contents**](#toc1)* |

---

**DIVIDEND POLICY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not previously paid cash dividends on our common stock. It is our current intention to invest our cash flow and earnings in the growth of our business and, therefore, we have no plans to pay cash dividends for the foreseeable future. Additionally, our ability to pay dividends is limited by restrictions on our ability to pay dividends and make certain other restricted payments under the terms of our term loan. Investors should not purchase our common stock with the expectation of receiving cash dividends.

---

| |
|:---|
| S-8 |
| *[**Table of Contents**](#toc1)* |

---

**DILUTION**

If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share of our common stock and the "as adjusted" net tangible book value per share of our common stock upon the closing of this offering.

Net tangible book value per share of our common stock is determined by subtracting our total liabilities from the amount of our total tangible assets (total assets less intangible assets) and then dividing the difference by the number of shares of our common stock deemed to be outstanding at that date. As of September 30, 2022, we had a net tangible book value of approximately $2.7 million, or $0.05 per share of common stock.

Our pro forma net tangible book value as of September 30, 2022 was approximately $4.2 million, or $0.07 per share after giving effect to our receipt of net proceeds of approximately $1.5 million from our sale of 630,532 shares of our common stock pursuant to the 2022 EDA subsequent to September 30, 2022.

After giving effect to the sale of shares of our common stock in this offering at an offering price of $1.75 per share, and after deducting estimated offering commissions and expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2022 would have been approximately $11.0 million, or $0.18 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of approximately $0.11 per share to existing stockholders and an immediate dilution of $1.57 per share to new investors purchasing securities in this offering.

The following table illustrates this dilution on a per share basis:

---

| | | |
|:---|:---|:---|
| Public offering price per share |  | $1.75 |
| &nbsp;&nbsp;&nbsp;&nbsp; Pro forma net tangible book value per share as of September 30, 2022 | $0.07 |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Increase in net tangible book value per share attributable to this offering | 0.11 |  |
| Pro forma as adjusted net tangible book value per share after this offering |  | 0.18 |
| Dilution per share to new investors purchasing in this offering |  | $1.57 |

---

If the underwriter fully exercises its option to purchase additional shares of our common stock, the pro forma as adjusted net tangible book value per share after giving effect to this offering would be $0.19 per share, which amount represents an immediate increase in pro forma as adjusted net tangible book value of $0.12 per share of our common stock to existing stockholders, and an immediate dilution to new investors purchasing in this offering of $1.56 per share.

Unless otherwise indicated, the number of shares of our common stock to be outstanding immediately after this offering is based on 57,496,003 shares of our common stock outstanding as of September 30, 2022, but excludes the following as of such date:

· 5,025,003 shares of our common stock issuable upon the exercise of options under our 2011 Equity Incentive Plan and 2015 Stock Incentive Plan, outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.87 per share;

· 539,000 shares of our common stock issuable upon the warrants outstanding as of September 30, 2022, with a weighted average exercise price of approximately $3.80 per share;

· 738,135 restricted stock units outstanding under our 2015 Stock Incentive Plan as of September 30, 2022, with a weighted average price of $3.02 per share; and

· an aggregate of 1,928,740 shares of common stock reserved for future issuance as of September 30, 2022, under our 2015 Stock Incentive Plan.

Unless otherwise indicated, this prospectus reflects and assumes the following:

· no additional issuances, exercises or forfeitures of options and warrants, other than as described above;

· no exercise of the outstanding options and warrants described above; and

· no exercise by the underwriter of its option to purchase additional shares of our common stock.

---

| |
|:---|
| S-9 |
| *[**Table of Contents**](#toc1)* |

---

**DESCRIPTION OF COMMON STOCK**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of all material characteristics of our common stock as set forth in our second amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by reference to our second amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to our SEC filings. For more information, see "*Where You Can Find More Information*."

**General**

We may issue shares of our common stock from time to time. We are currently authorized to issue 100,000,000 shares of common stock, par value $0.001 per share.

As of February 10, 2023, there were 58,139,788 shares of our common stock outstanding.

**Common Stock**

Our common stock is listed on the NYSE American Market and traded under the symbol "VNRX." On February 16, 2023, the last reported sale price of our common stock on the NYSE American Market was $2.04 per share.

Holders of shares of our common stock are entitled to one vote per share held of record on all matters submitted to a vote of stockholders, including the election of directors. The holders are entitled to receive dividends when, as and if declared by our board of directors, in its discretion, out of funds legally available therefor. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to share ratably in all of our assets remaining after payment of liabilities. The holders of our common stock have no preemptive or other subscription rights, and there are no conversion rights or redemption or sinking fund provisions with respect to such shares. All of the outstanding shares of our common stock are, and the shares of our common stock when issued will be, fully paid and non-assessable.

The material terms of our common stock are further described under the heading "*Description of Capital Stock*" in the accompanying prospectus.

**Holders**

As of February 10, 2023 there were approximately 144 holders of record of our common stock. The actual number of holders of our common stock is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by banks, brokers, dealers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

---

| |
|:---|
| S-10 |
| *[**Table of Contents**](#toc1)* |

---

**UNDERWRITING**

Newbridge Securities Corporation is acting as sole underwriter of this offering. We have entered into an underwriting agreement with Newbridge Securities Corporation, dated February 17, 2023, with respect to the shares of our common stock subject to this offering. Subject to the terms and conditions in the underwriting agreement, we have agreed to sell to the underwriter, and the underwriter has agreed to purchase from us on a firm commitment basis, the number of shares of our common stock set forth opposite its name in the table below:

---

| | |
|:---|:---|
| **Underwriter** | **Number of Shares** |
| Newbridge Securities Corporation | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4300000 |
| **Total** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4300000 |

---

The underwriting agreement provides that the obligation of the underwriter to purchase all of the shares being offered to the public is subject to approval of legal matters by counsel and the satisfaction of other conditions. These conditions include, among others, the continued accuracy of representations and warranties made by us in the underwriting agreement, delivery of legal opinions and the absence of any material changes in our assets, business or prospects after the date of this prospectus. The underwriter is obligated to purchase all of our shares of common stock in this offering, other than those covered by the option described below, if it purchases any of our shares of common stock.

The underwriter has advised us that it proposes to offer the common stock directly to the public at the public offering price listed on the cover page of this prospectus. In addition, the underwriter may offer some of the shares to other securities dealers at such price less a concession of $0.0735 per share. After the initial offering of the shares of common stock, the public offering price or any other term of the offering by the underwriter may be changed by the underwriter.

Pursuant to the underwriting agreement, we have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act, or to contribute to payments which the underwriter or other indemnified parties may be required to make in respect of any such liabilities.

**Option**

We have granted the underwriter an option, exercisable from time to time for up to 30 days after the date of this prospectus, to purchase a maximum of 645,000 additional shares of common stock from us. If the underwriter exercises all or part of this option, it will purchase shares covered by the option at the public offering price that appears on the cover page of this prospectus supplement, less the underwriting discounts and commissions.

**Commissions and Expenses**

The following table provides information regarding the amount of the underwriting discounts and commissions to be paid to the underwriter by us. These amounts are shown assuming both no exercise and full exercise of the underwriter's option to purchase additional shares of common stock.

---

| | | | |
|:---|:---|:---|:---|
|  | **Per Share** | **Total** <br> **Without** <br> **Option** | **With** <br> **Option** |
| Underwriting discounts and commissions paid by us | $0.1225 | $526750 | $605763 |
| Proceeds, before expenses, to us | $1.6275 | $6998.250 | $8047988 |

---

The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $125,000, which includes our legal, accounting and printing costs and various other fees associated with registration of the offering of our common stock. We have also agreed to reimburse the underwriter for its reasonable out-of-pocket expenses actually incurred in the offering, including fees and disbursements of legal counsel to the underwriter of up to $80,000.

**Purchases by Affiliates**

Certain family members of one of our directors have agreed to purchase an aggregate of 234,000 shares in this offering at the same price per share offered to the public.

---

| |
|:---|
| S-11 |
| *[**Table of Contents**](#toc1)* |

---

**Lock-Up Agreements**

We and each of our officers and directors have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, for a period of three months from the date of this prospectus supplement, without the prior written consent of Newbridge Securities Corporation; *provided*, however, that we may sell shares of common stock under our at-the-market offering program with Jefferies following such date that is 60 days from the date of this prospectus.

The underwriter may, in its sole discretion and at any time or from time to time, release all or any portion of the common stock or other securities subject to the lock-up agreement. Any determination to release any common stock would be based upon a number of factors at the time of determination, which may include the market price of the common stock, the liquidity of the trading market of the common stock, general market conditions, the number of shares of common stock or other securities proposed to be sold or otherwise transferred and the timing, purposes and terms of the proposed sale or other transfer. The underwriter does not have any present intention, agreement or understanding, implicit or explicit, to release any of the shares of common stock or other securities subject to the lock-up agreements prior to the expiration of the lock-up period described above.

**Stabilization**

Until the distribution of shares of common stock is complete, SEC rules may limit the ability of the underwriter to bid for and purchase shares of our common stock. As an exception to these rules, underwriters are permitted to engage in certain transactions which stabilize the price of the shares of common stock, which may include short sales, covering transactions and stabilizing transactions. Short sales involve sales of shares of common stock in excess of the number of shares to be purchased by the underwriter in the offering, which creates a short position. "Covered" short sales are sales made in an amount not greater than the underwriter's option to purchase additional shares of common stock from us in the offering. The underwriter may close out any covered short position by either exercising its option to purchase additional shares of common stock or purchasing shares of common stock in the open market. In determining the source of shares of common stock to close out the covered short position, the underwriter will consider, among other things, the price of shares of common stock available for purchase in the open market as compared to the share price at which they may purchase through its option to purchase additional shares. "Naked" short sales are any sales in excess of such option. The underwriter must close out any naked short position by purchasing shares of common stock in the open market. A naked short position is more likely to be created if the underwriter are concerned that there may be downward pressure on the price of the shares of common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the shares of common stock made by the underwriter in the open market prior to the completion of the offering.

The underwriter may also impose a penalty bid. This occurs when a particular underwriter repays to the other underwriter a portion of the underwriting discount received by it because the representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.

Neither we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described above might have on our shares of common stock. Any of these activities may have the effect of preventing or retarding a decline in the market price of our shares of common stock. They may also cause the price of the shares of common stock to be higher than the price that would otherwise exist in the open market in the absence of these transactions. If the underwriter commences any of these transactions, it may discontinue them at any time without notice.

We expect that delivery of the shares will be made to investors on or about February 22, 2023 (such settlement being referred to as "T+2").

In the ordinary course of their various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for their own account and for the accounts of their clients and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

---

| |
|:---|
| S-12 |
| *[**Table of Contents**](#toc1)* |

---

**Electronic Prospectus**

This prospectus may be made available in electronic format on Internet sites or through other online services maintained by the underwriter or its affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. Other than this prospectus in electronic format, any information on the underwriter's or its affiliates' websites and any information contained in any other website maintained by the underwriter or any affiliate of the underwriter is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus supplement forms a part, has not been approved and/or endorsed by us or the underwriter and should not be relied upon by investors.

**Additional Relationships**

The underwriter and its affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. The underwriter and its affiliates may provide from time to time in the future in the ordinary course of their business certain commercial banking, financial advisory, investment banking and other services to us for which they will be entitled to receive customary fees and expenses.

---

| |
|:---|
| S-13 |
| *[**Table of Contents**](#toc1)* |

---

**LEGAL MATTERS**

Certain legal matters relating to this offering will be passed upon for us by Stradling Yocca Carlson & Rauth, a Professional Corporation in Newport Beach, California. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, Boston, Massachusetts, is acting as counsel for the underwriter in connection with this offering.

**EXPERTS**

The consolidated financial statements of VolitionRx Limited as of December 31, 2021 and 2020 and for each of the years in the two-year period ended December 31, 2021, have been incorporated by reference herein in reliance upon the reports of Sadler, Gibb & Associates, LLC, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.

**INCORPORATION OF CERTAIN INFORMATION BY REFERENCE**

The SEC allows us to "incorporate" into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this prospectus.

Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.

We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, between the date of this prospectus supplement until the offering of the security covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been "furnished" and not "filed" in accordance with SEC rules:

· our Annual Report on [Form 10-K for the year ended December 31, 2021 filed with the SEC on March 30, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222001740/0001477932-22-001740-index.htm) ;

· our Quarterly Reports on [Form 10-Q for the fiscal quarters ended March 31, 2022 filed with the SEC on May 11, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222003197/0001477932-22-003197-index.htm) , [June 30, 2022 filed with the SEC on August 10, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222005796/0001477932-22-005796-index.htm) , and [September 30, 2022 filed with the SEC on November 14, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222008533/0001477932-22-008533-index.htm) ;

· the information specifically incorporated by reference into our [Annual Report on Form 10-K for the year ended December 31, 2021 from our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222002686/0001477932-22-002686-index.htm) ;

· our Current Reports on Form 8-K filed with the SEC on [March 29, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222001691/0001477932-22-001691-index.htm) , [May 20, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222003728/0001477932-22-003728-index.htm) , [June 14, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222004360/0001477932-22-004360-index.htm) , [August 2, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222005563/0001477932-22-005563-index.htm) , [August 16, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222006194/0001477932-22-006194-index.htm) , and [November 25, 2022](http://www.sec.gov/Archives/edgar/data/93314/000147793222008884/0001477932-22-008884-index.htm) ; and

· the description of our common stock contained in our registration statement on [Form 8-A filed with the SEC on February 3, 2015](http://www.sec.gov/Archives/edgar/data/93314/000107878215000156/0001078782-15-000156-index.htm) , [Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 20, 2020](http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex4z1.htm) , and any other amendments or reports filed for the purpose of updating such description.

These filings have not been included in or delivered with this prospectus. We hereby undertake to provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates. To request such materials, please contact Mr. Rodney Rootsaert, our Corporate Secretary, at c/o Corporate Secretary, VolitionRx Limited, 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014, by telephone at +1 (646) 650-1351 or by email at *notice@volition.com*. These documents are also available free of charge through the "Investors" section on our website at *www.volition.com* as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC.

You should rely only on the information contained in this prospectus, in any document incorporated by reference herein, or in any free writing prospectuses we may provide to you in connection with this offering. Neither we nor Newbridge Securities Corporation have authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you.

The information contained in this prospectus, and in the documents incorporated by reference herein, is accurate only as of the date such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates.

---

| |
|:---|
| S-14 |
| *[**Table of Contents**](#toc1)* |

---

**WHERE YOU CAN FIND MORE INFORMATION**

We file annual, quarterly and current reports and other information with the SEC. Our filings with the SEC are available from the SEC's internet site at *http://www.sec.gov*, which contains reports, proxy and information statements, and other information regarding issuers that file electronically.

This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is included in the registration statement. The registration statement contains more information regarding us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC's website.

---

| |
|:---|
| S-15 |
| *[**Table of Contents**](#toc1)* |

---

**$100,000,000**

![](vnrx_424b5img5.jpg)

**VOLITIONRX LIMITED**

**Common Stock**

**Warrants**

**Units** 

___________________________________________________________________________________________________________

We may offer and sell, from time to time in one or more offerings, any combination of common stock, warrants exercisable for shares of our common stock, or units having an aggregate initial offering price not to exceed $100,000,000. The units may consist of any combination of securities described in this prospectus.

This prospectus provides a general description of the securities we may offer. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplement may also add, update or change information in this prospectus. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference herein or therein, carefully before you invest in any of the securities offered pursuant to this prospectus. **This prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities.**

These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or dealers or through a combination of these methods on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled "Plan of Distribution" in this prospectus. We will describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities with respect to which this prospectus is being delivered, we will set forth in a prospectus supplement the names of such agents, underwriters or dealers and any applicable fees, commissions, discounts and over-allotment options. We will also set forth in a prospectus supplement the price to the public of such securities and the net proceeds that we expect to receive from such sale.

Our common stock is currently quoted on the NYSE American Market under the symbol "VNRX." On September 22, 2021, the last reported sale price of our common stock on the NYSE American Market was $3.13 per share.

**INVESTING IN THE SECURITIES WE MAY OFFER INVOLVES VARIOUS RISKS. WE STRONGLY RECOMMEND THAT YOU READ CAREFULLY THE RISKS WE DESCRIBE IN THIS PROSPECTUS AS WELL AS IN ANY ACCOMPANYING PROSPECTUS SUPPLEMENT AND THE RISK FACTORS IN OUR MOST CURRENT REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, FOR A FULLER UNDERSTANDING OF THE RISKS AND UNCERTAINTIES THAT WE FACE. SEE THE SECTION ENTITLED "RISK FACTORS" ON PAGE 3.**

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

The date of this prospectus is November 8, 2021

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **PROSPECTUS** | **Page** |
| [ABOUT THIS PROSPECTUS](#about2) | 1 |
| [PROSPECTUS SUMMARY](#pro2) | 2 |
| [RISK FACTORS](#risk2) | 3 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION](#cout2) | 4 |
| [USE OF PROCEEDS](#use2) | 5 |
| [GENERAL DESCRIPTION OF SECURITIES](#gen2) | 6 |
| [DESCRIPTION OF CAPITAL STOCK](#disc2) | 7 |
| [DESCRIPTION OF WARRANTS](#disc3) | 9 |
| [DESCRIPTION OF UNITS](#disc4) | 10 |
| [PLAN OF DISTRIBUTION](#plan2) | 11 |
| [LEGAL MATTERS](#leg2) | 13 |
| [EXPERTS](#exp2) | 13 |
| [INCORPORATION OF CERTAIN INFORMATION BY REFERENCE](#incorp2) | 14 |
| [WHERE YOU CAN FIND MORE INFORMATION](#ehere2) | 15 |

---

**ABOUT THIS PROSPECTUS**

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a "shelf" registration process. Under this shelf registration process, we may from time to time offer and sell any combination of the securities described in this prospectus in one or more offerings with an aggregate initial offering price not to exceed $100,000,000. We have provided to you in this prospectus a general description of the securities we may offer. Each time we sell any of our securities under this prospectus, we will, to the extent required by law, provide a prospectus supplement that will contain specific information about the terms of the offering.

We may add, update or change any of the information contained in this prospectus or in any accompanying prospectus supplement we may authorize to be delivered to you. To the extent there is a conflict between the information contained in this prospectus and any accompanying prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date – for example, a document incorporated by reference in this prospectus or any prospectus supplement – the statement in the document having the later date shall modify or supersede such earlier statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. This prospectus, together with any accompanying prospectus supplement, includes all material information relating to an offering pursuant to this registration statement.

You should rely only on the information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

This prospectus and any accompanying prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus and any accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. This prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities.

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered pursuant to this prospectus. The registration statement, including the exhibits, can be read on the SEC's website or at the SEC's offices mentioned under the heading "Where You Can Find More Information."

We may sell the securities to or through underwriters, dealers or agents or directly to purchasers. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will provide to you each time we offer securities, will set forth the names of any underwriters, dealers or agents involved in the sale of the securities, and any applicable fee, commission or discount arrangements with them. See "Plan of Distribution."

Unless we state otherwise or the context indicates otherwise, references to the "Company", "VolitionRx", "we", "us", and "our" in this prospectus refer to VolitionRx Limited and its subsidiaries. Our fiscal year ends on December 31 of each calendar year. Nucleosomics<sup>TM</sup>, and Nu.Q<sup>®</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this prospectus are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

---

| |
|:---|
| 1 |
| *[**Table of Contents**](#toc2)* |

---

**PROSPECTUS SUMMARY**

*This summary highlights selected information that is presented in greater detail elsewhere in this prospectus or incorporated by reference in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities, and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus, the applicable prospectus supplement and any related free writing prospectus carefully, including the risks of investing in our securities discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.*

**Overview**

We are a multi-national epigenetics company that applies our Nucleosomics<sup>TM</sup> platform through our subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and some other diseases, including sepsis and COVID-19, that are associated with the presence in the blood of networks of fibers released from activated neutrophils, a phenomenon known as NETosis. We hope that through earlier diagnosis we can help save and improve the quality of human and animals' lives throughout the world.

Our assays are based on the science of Nucleosomics<sup>TM</sup>, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid, since changes in these parameters are an indication that disease is present.

Our approach is to investigate the epigenetic structure of chromatin and nucleosomes rather than investigating only the DNA sequence. We are continuously developing new technologies including:

· A suite of low cost Nu.Q<sup>®</sup> immunoassays that can accurately measure nucleosomes containing numerous epigenetic signals or structures, now being developed on a range of different enzyme-linked immunosorbent assay, or ELISA, platforms.

· Nu.Q<sup>®</sup> Capture technology to isolate or enrich nucleosomes containing particular epigenetic signals or structures for a wide range of potential scientific and medical applications, e.g., the enrichment of nucleosomes of tumor origin in blood samples taken from cancer patients.

· The production of synthetic (recombinant) nucleosomes, containing exact defined epigenetic signals and structures, which is now in-house. These nucleosomes are used to ensure maximal accuracy of Nu.Q<sup>®</sup> immunoassay tests but also have many other applications including Research Use Only, or RUO, kits and as tools in epigenetic drug development.

We have also developed the use of the Nu.Q<sup>®</sup> technology in veterinary applications and launched its first product, the Nu.Q<sup>®</sup> Vet Cancer Screening Test, in the fourth quarter of 2020. We are in the process of developing additional veterinary products, including a treatment monitoring test, a disease recurrence test and a point-of-care platform. Our extensive intellectual property portfolio includes the coverage of veterinary applications.

**Corporate Information**

We are a Delaware corporation. Our executive offices are located at 13215 Bee Cave Parkway, Suite 125, Galleria Oaks B, Austin, Texas 78738, and our telephone number is +1 (646) 650-1351. We maintain a website at *www.volition.com*. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to such reports are available to you free of charge through the Investors section of *www.volition.com* as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. The information contained on or accessed through our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be a part of this prospectus or in deciding whether to purchase our securities. We have included our website address only as an inactive textual reference and do not intend it to be an active link to our website.

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#toc2)* |

---

**RISK FACTORS**

Before making an investment decision, you should carefully consider the risks described under "Risk Factors" in the applicable prospectus supplement and in our most recent Annual Report on Form 10-K, or any updates in our Quarterly Reports on Form 10-Q, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light of your particular investment objectives and financial circumstances. The risks so described are not the only risks facing our company. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. For more information, see the information included under the heading "Where You Can Find More Information."

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#toc2)* |

---

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION**

This prospectus, any accompanying prospectus supplement, and the documents incorporated by reference herein and therein, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, including statements regarding estimates, future events, our future financial performance, business strategy and plans and objectives of management for future operations, including with respect to us specifically and the cancer diagnostics industry in general, are forward-looking statements. We have attempted to identify estimates and forward-looking statements by terminology including "aims," "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "goal," "intends," "may," "plans," "potential," "predicts," "seeks," "should," "suggests," "targets" or "will" or the negative of these terms or other comparable terminology. Although we do not make estimates or forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Our estimates and forward-looking statements are based on our current assumptions and expectations about future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry's actual results, levels of activity, performance or achievements to vary materially from those expressed or implied by these estimates and forward-looking statements.

Factors that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed under the section entitled "Risk Factors" in this prospectus, any accompanying prospectus supplement, and in any documents incorporated by reference herein and therein. Readers should carefully review this information as well as other risks and uncertainties described in other filings with the SEC that we may make after the filing date of this prospectus. See the information included under the heading "Where You Can Find More Information."

Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any estimates or forward-looking statements. All estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by applicable law or regulation, we undertake no obligation to update or to review any estimate and/or forward-looking statement. In light of these risks and uncertainties, we cannot assure you that the estimates or forward-looking statements contained in this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, will in fact occur. You should not place undue reliance on these estimates and forward-looking statements.

We qualify all of our forward-looking statements by these cautionary statements.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#toc2)* |

---

**USE OF PROCEEDS**

We intend to use the net proceeds we receive from the sale of our securities offered by us hereby for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.

We may set forth additional information regarding the use of proceeds from the sale of securities we offer under this prospectus in a prospectus supplement relating to the specific offering. We have not determined the amount of net proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of net proceeds.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#toc2)* |

---

**GENERAL DESCRIPTION OF SECURITIES**

We, directly or through agents, dealers or underwriters designated from time to time, may offer, issue and sell, together or separately, in one or more offerings, up to $100,000,000 in the aggregate, inclusive of any exercise price thereof, of:

· shares of our common stock, par value $0.001 per share;

· warrants to purchase shares of our common stock;

· units comprised of one or more shares of common stock and warrants in any combination; or

· any combination of the foregoing, each on terms to be determined at the time of sale.

The common stock, warrants and units are collectively referred to herein as the securities. This prospectus provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will, to the extent required by law, provide you with a prospectus supplement that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information in this prospectus. The securities involve various risks that we will describe in the section entitled "Risk Factors" that will be included in each prospectus supplement. For more details, see the information included under the heading "About this Prospectus."

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#toc2)* |

---

**DESCRIPTION OF CAPITAL STOCK**

The following is a summary of all material characteristics of our capital stock as set forth in our second amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by reference to our second amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to our SEC filings. For more information, see "Where You Can Find More Information."

**Common Stock**

We have authority under our second amended and restated certificate of incorporation to issue up to 100,000,000 shares of our common stock, par value $0.001 per share. As of September 22, 2021, there were 53,222,361 shares of our common stock issued and outstanding.

Holders of shares of our common stock are entitled to one vote per share held of record on all matters submitted to a vote of stockholders, including the election of directors. The holders are entitled to receive dividends when, as and if declared by our board of directors, in its discretion, out of funds legally available therefor. In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to share ratably in all of our assets remaining after payment of liabilities. The holders of our common stock have no preemptive or other subscription rights, and there are no conversion rights or redemption or sinking fund provisions with respect to such shares. All of the outstanding shares of our common stock are, and the shares of our common stock when issued will be, fully-paid and nonassessable.

**Registration Rights**

Cotterford Company Limited, or Cotterford, is entitled to certain "piggy-back" registration rights where, if at any time, there is not an effective registration statement covering all of the Registrable Securities (as defined in the Cotterford Agreement) and we determine to prepare and file with the SEC a registration statement relating to an offering for our own account or the account of others, under the Securities Act, of any of our equity securities (subject to certain exceptions), Cotterford can require us to register its Registrable Securities (subject to cutbacks at the request of the underwriters, if applicable). These rights are provided under the terms of a Common Stock Purchase Agreement dated August 8, 2018, or the Cotterford Agreement. We generally must pay all expenses relating to any such registration, other than Cotterford's counsel, broker's commissions, discounts or fees and transfer taxes. These registration rights terminate automatically upon the earlier of the sale of the Registrable Securities and the date such registrable securities may be resold without volume or manner-of-sale limitations pursuant to Rule 144 under the Securities Act. The Registrable Securities were registered for resale pursuant to a Registration Statement on Form S-3, File No. 333-227731, initially declared effective by the SEC on October 15, 2018.

**Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws**

Certain provisions of Delaware law, our second amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging such proposals, including proposals that are priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could result in an improvement of their terms.

*Certificate of Incorporation and Bylaws*. Our second amended and restated certificate of incorporation and amended and restated bylaws include provisions that:

· require that any action to be taken by our stockholders be effected at a duly-called annual or special meeting and not by written consent;

· specify that special meetings of our stockholders can be called only by the board of directors, the chairman of the board, or the chief executive officer (or the president if there is no chief executive officer);

· establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors;

· provide that the number of directors on our board of directors is fixed exclusively by our board of directors;

· provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;

· establish the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain derivative actions or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the General Corporation Law of the State of Delaware, or the DGCL, or any action asserting a claim governed by the internal affairs doctrine; and

· provide that there is no right to cumulate votes with respect to any shares of capital stock.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#toc2)* |

---

*Delaware anti-takeover statute.* We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:

· prior to the date of the transaction, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

· upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

· at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3 % of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the "interested stockholder" and an "interested stockholder" is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation's outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may discourage business combinations or other attempts that might result in a premium over the market price for the shares of common stock held by our stockholders. The provisions of DGCL, our restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.

**NYSE American Market**

Our common stock is listed on the NYSE American Market and traded under the symbol "VNRX." On September 22, 2021, the last reported sale price for our common stock on the NYSE American Market was $3.13 per share.

**Transfer Agent and Registrar**

The transfer agent and registrar for our common stock is VStock Transfer, LLC. The address of VStock Transfer, LLC is 18 Lafayette Place, Woodmere, New York 11598, and the telephone number is (212) 828-8436.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#toc2)* |

---

**DESCRIPTION OF WARRANTS**

We may offer, sell and issue, from time to time, warrants to purchase shares of our common stock. The warrants may be issued independently or together with shares of our common stock and may be attached to or separate from the shares of our common stock. If we issue warrants, they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which will be contracts between us and/or a bank or trust company, as warrant agent, and the holders of the warrants or an agent for the holders of the warrants, all as shall be set forth in the prospectus supplement relating to warrants being offered pursuant to such prospectus supplement. The forms of warrant agreements or warrant certificates, as applicable, relating to the warrants will be filed as exhibits to the registration statement of which this prospectus is part and/or will be incorporated by reference from reports that we file with the SEC.

The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all of the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.

Whenever warrants are to be issued and sold pursuant to this prospectus, we will file a prospectus supplement relating to that offer and sale which will specify (in each case as applicable):

· the number of shares of common stock purchasable upon exercise of the warrants and the exercise price at which such number of shares may be purchased upon exercise;

· the price or prices at which the warrants will be issued;

· the provisions, if any, for changes to or adjustments in the exercise price;

· the provisions, if any, for call rights or put rights relating to the warrants or the underlying shares of common stock;

· the date on which the right to exercise the warrants shall commence and the date on which the right will expire;

· if applicable, the number of warrants issued with each share of our common stock;

· if applicable, the date on and after which the warrants and the related common stock will be separately transferable; and

· any other terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants.

Until any warrants to purchase common stock are exercised, the holders of warrants will not be entitled, by virtue of being such holders, to vote, consent, receive dividends, receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter, or to exercise any rights whatsoever as our stockholders.

Each warrant will entitle the holder to purchase for cash such shares of our common stock at such exercise price as shall be in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void.

The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Upon receipt of payment and the warrant certificate properly completed and duly executed at the Company or the corporate trust office of the warrant agent, as applicable, or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the shares of our common stock purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#toc2)* |

---

**DESCRIPTION OF UNITS**

We may issue units comprised of one or more of the other securities described in this prospectus in any combination from time to time. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. If we issue units, they will be evidenced by unit agreements or unit certificates issued under one or more unit agreements, which will be contracts between us and the holders of the units or an agent for the holders of the units. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The forms of unit agreements or unit certificates, as applicable, relating to the units will be filed as exhibits to the registration statement that includes this prospectus, or as an exhibit to a filing with the SEC that is incorporated by reference into this prospectus.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#toc2)* |

---

**PLAN OF DISTRIBUTION**

We may sell our securities from time to time in any manner permitted by the Securities Act, including any one or more of the following ways:

· to investors through agents;

· directly to agents;

· to or through underwriters;

· to or through broker-dealers (acting as agent or principal);

· in a block trade;

· in ordinary brokerage transactions and transactions in which a broker solicits purchasers;

· in privately negotiated transactions;

· in "at the market" offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; and/or

· directly to purchasers, through a specific bidding or auction process or otherwise.

The securities may be sold at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices relating to the prevailing market prices or at negotiated prices.

Offers to purchase offered securities may be solicited by agents designated by us from time to time. Any agent involved in the offer or sale of the offered securities in respect of which this prospectus is delivered will be named, and any commissions payable by us will be set forth, in the applicable prospectus supplement. Unless otherwise set forth in the applicable prospectus supplement, any agent will be acting on a reasonable best efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the Securities Act, of the offered securities so offered and sold.

We will set forth in a prospectus supplement the terms of the offering of our securities, including:

· the name or names of any agents, underwriters or dealers;

· the purchase price of our securities being offered and the proceeds we will receive from the sale;

· any over-allotment options under which underwriters may purchase additional securities from us;

· any agency fees or underwriting discounts and commissions and other items constituting agents' or underwriters' compensation;

· the public offering price;

· any discounts or concessions allowed or reallowed or paid to dealers; and

· any securities exchanges on which such securities may be listed.

If offered securities are sold to the public by means of an underwritten offering, either through underwriting syndicates represented by managing underwriters or directly by the managing underwriters, we will execute an underwriting agreement with an underwriter or underwriters, and the names of the specific managing underwriter or underwriters, as well as any other underwriters, will be set forth in the applicable prospectus supplement. In addition, the terms of the transaction, including commissions, discounts and any other compensation of the underwriters and dealers, if any, will be set forth in the applicable prospectus supplement, which prospectus supplement will be used by the underwriters to make resales of the offered securities. If underwriters are utilized in the sale of the offered securities, the offered securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including:

· transactions on the NYSE American Market or any other organized market where the securities may be traded;

· in the over-the-counter market;

· in negotiated transactions; or

· under delayed delivery contracts or other contractual commitments.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#toc2)* |

---

We may grant to the underwriters options to purchase additional offered securities to cover over-allotments, if any, at the public offering price with additional underwriting discounts or commissions, as may be set forth in the applicable prospectus supplement. If we grant any over-allotment option, the terms of the over-allotment option will be set forth in the applicable prospectus supplement.

We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement.

We may indemnify agents, underwriters and dealers against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make in respect of such liabilities. Agents, underwriters or dealers, or their respective affiliates, may be customers of, engage in transactions with or perform services for us or our respective affiliates, in the ordinary course of business.

Unless otherwise specified in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other than our common stock, which is traded on the NYSE American Market. We may elect to list any other class or series of securities on any exchange and, in the case of our common stock, on any additional exchange. However, unless otherwise specified in the applicable prospectus supplement, we will not be obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the offered securities.

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

To comply with the securities laws of certain states, if applicable, the securities offered by this prospectus will be offered and sold in those states only through registered or licensed brokers or dealers.

In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#toc2)* |

---

**LEGAL MATTERS**

Certain legal matters, including the validity of the issuance of the securities offered by this prospectus, will be passed on by Stradling Yocca Carlson & Rauth, a Professional Corporation, Newport Beach, California.

**EXPERTS**

The consolidated financial statements of VolitionRx Limited as of December 31, 2020 and 2019 and for each of the years in the two-year period ended December 31, 2020 have been incorporated by reference herein and in the registration statement in reliance upon the reports of Sadler, Gibb & Associates, LLC, our independent registered public accountant, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The report of Sadler, Gibb & Associates, LLC dated March 22, 2021 notes that our net losses since inception and accumulation of a significant deficit raise substantial doubt that we will be able to continue as a going concern without further financing.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#toc2)* |

---

**INCORPORATION OF CERTAIN INFORMATION BY REFERENCE**

The SEC allows us to "incorporate" into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this prospectus.

Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. For more information, see "About this Prospectus."

We incorporate by reference, as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including any documents filed after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been "furnished" and not "filed" in accordance with SEC rules:

· our Annual Report on [Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 22, 2021](http://www.sec.gov/Archives/edgar/data/0000093314/000107878221000262/0001078782-21-000262-index.htm) ;

· our Quarterly Reports on Form 10-Q for the fiscal quarters ended [March 31, 2021](http://www.sec.gov/Archives/edgar/data/0000093314/000107878221000429/0001078782-21-000429-index.htm) and [June 30, 2021](http://www.sec.gov/Archives/edgar/data/0000093314/000147793221005342/0001477932-21-005342-index.htm) , as filed with the SEC on May 11, 2021 and August 11, 2021, respectively;

· our Definitive Proxy Statement on [Schedule 14A, as filed with the SEC on April 29, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000404/0001078782-21-000404-index.htm) (to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the year ended December 31, 2020);

· our Current Reports on Form 8-K as filed with the SEC on each of [January 15, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000055/0001078782-21-000055-index.htm) , [February 2, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000085/0001078782-21-000085-index.htm) , [February 9, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000107/0001078782-21-000107-index.htm) , [February 12, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000128/0001078782-21-000128-index.htm) , [March 29, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000279/0001078782-21-000279-index.htm) and [June 22, 2021](http://www.sec.gov/Archives/edgar/data/93314/000107878221000582/0001078782-21-000582-index.htm) ; and

· the description of our common stock contained in our registration statement on [Form 8-A, as filed with the SEC on February 3, 2015](http://www.sec.gov/Archives/edgar/data/93314/000107878215000156/0001078782-15-000156-index.htm) , [Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2019](http://www.sec.gov/Archives/edgar/data/93314/000107878220000134/f10k123119_ex4z1.htm) , as filed with the SEC on February 20, 2020, and any other amendments or reports filed for the purpose of updating such description.

We hereby undertake to provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into this prospectus. To request such materials, please contact Mr. Rodney Rootsaert, our Corporate Secretary at c/o Corporate Secretary, VolitionRx Limited, 13215 Bee Cave Parkway, Suite 125, Galleria Oaks B, Austin, Texas 78738 by telephone at +1 (646) 650-1351 or by email at *notice@volition.com*. These documents are also available free of charge through the investors section on our website at *www.volition.com* as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC.

You should rely only on the information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#toc2)* |

---

**WHERE YOU CAN FIND MORE INFORMATION**

We file annual, quarterly and current reports and other information with the SEC. Our filings with the SEC are available from the SEC's website at *www.sec.gov*, which contains reports, proxy and information statements, and other information regarding issuers that file electronically.

This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is included in the registration statement. The registration statement contains more information regarding us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC's website.

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#toc2)* |

---

**4,300,000 Shares**

**Common Stock**

**PROSPECTUS SUPPLEMENT**

**Newbridge Securities Corporation**

**February 17, 2023**